MX2021003643A - Derivados de terpenoides y usos de los mismos. - Google Patents

Derivados de terpenoides y usos de los mismos.

Info

Publication number
MX2021003643A
MX2021003643A MX2021003643A MX2021003643A MX2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A MX 2021003643 A MX2021003643 A MX 2021003643A
Authority
MX
Mexico
Prior art keywords
terpinoid
derivatives
compounds
compositions
useful
Prior art date
Application number
MX2021003643A
Other languages
English (en)
Inventor
Gene Hung
Stephen W Kaldor
Bohan Jin
Qing Dong
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of MX2021003643A publication Critical patent/MX2021003643A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J73/00Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes

Abstract

Se describen en la presente derivados terpenoides como inhibidores de NRF2 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones objetivo son útiles para el tratamiento de enfermedades inflamatorias.
MX2021003643A 2018-09-28 2019-09-23 Derivados de terpenoides y usos de los mismos. MX2021003643A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862738762P 2018-09-28 2018-09-28
US201862770569P 2018-11-21 2018-11-21
US201962808192P 2019-02-20 2019-02-20
US201962823846P 2019-03-26 2019-03-26
PCT/US2019/052472 WO2020068689A1 (en) 2018-09-28 2019-09-23 Terpinoid derivatives and uses thereof

Publications (1)

Publication Number Publication Date
MX2021003643A true MX2021003643A (es) 2021-08-19

Family

ID=69953539

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003643A MX2021003643A (es) 2018-09-28 2019-09-23 Derivados de terpenoides y usos de los mismos.

Country Status (9)

Country Link
US (1) US20220017566A1 (es)
EP (1) EP3856755A4 (es)
JP (1) JP2022501445A (es)
CN (1) CN113366010A (es)
AU (1) AU2019346395A1 (es)
BR (1) BR112021005919A2 (es)
CA (1) CA3114354A1 (es)
MX (1) MX2021003643A (es)
WO (1) WO2020068689A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022007595A (es) * 2019-12-19 2022-07-19 Reata Pharmaceuticals Inc Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos.
WO2022126129A1 (en) * 2020-12-11 2022-06-16 Reata Pharmaceuticals, Inc. Synthetic triterpenoids for use in therapy
CN117015548A (zh) * 2021-01-18 2023-11-07 里亚塔医药公司 合成的熊果酸衍生物和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071632B2 (en) * 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
TWI453023B (zh) * 2008-04-18 2014-09-21 Reata Pharmaceuticals Inc 抗氧化發炎調節劑:在c-17處具有胺基及其他修飾之齊墩果酸衍生物
WO2013188818A1 (en) * 2012-06-15 2013-12-19 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
JP2015527407A (ja) * 2012-09-10 2015-09-17 アッヴィ・インコーポレイテッド グリチルレチン酸誘導体およびその使用方法
CA2882417C (en) * 2012-09-10 2021-04-20 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
TWI716341B (zh) * 2013-08-23 2021-01-21 美商瑞塔醫藥有限責任公司 使用齊墩果酸(bardoxolone methyl)或其類似物治療和預防內皮功能障礙之方法

Also Published As

Publication number Publication date
AU2019346395A1 (en) 2021-04-22
JP2022501445A (ja) 2022-01-06
WO2020068689A1 (en) 2020-04-02
BR112021005919A2 (pt) 2021-07-27
CA3114354A1 (en) 2020-04-02
CN113366010A (zh) 2021-09-07
US20220017566A1 (en) 2022-01-20
EP3856755A1 (en) 2021-08-04
EP3856755A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
WO2018136264A9 (en) Pyridine compounds as allosteric shp2 inhibitors
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
EP3693369A3 (en) Bromodomain inhibitors
MX2023002507A (es) Inhibidores de cd73.
EP3866781A4 (en) NEW COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES
ZA201904522B (en) Heterocyclic inhibitors of mct4
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
NZ788133A (en) Cd73 inhibitors
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2020005841A (es) Derivados de 1,2,4-oxadiazol como inhibidores de histona-desacetilasa 6.
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ZA202003281B (en) Heterocycle substituted pyridine derivative antifungal agents
EP3685840A4 (en) PHARMACEUTICAL COMPOSITION OF COMPOUNDS FOR TREATING INFLAMMATORY SKIN DISEASES
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
EP3804736A4 (en) PHARMACEUTICAL COMPOSITION WITH MESENCHYMAL STEM CELLS AS AN EFFECTIVE INGREDIENT TO PREVENT OR TREAT AN INFLAMMATORY DISEASE
WO2018211324A8 (en) Prodrugs for the treatment of disease
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação